Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Forxiga Filed for Chronic Kidney Disease in Japan: AZ
December 15, 2020
- Authorized Generics for Lyrica, ComPlavin, Memary Dry Syrup Now Available
December 14, 2020
- Astellas Sees More R&D Collaborations in Gene Therapy, I/O as It Looks beyond Xtandi LOE
December 14, 2020
- 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
- Takeda Launches Buccal Midazolam for Status Epilepticus
December 14, 2020
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- Chugai to Develop Regeneron’s COVID-19 Antibody Cocktail in Japan
December 11, 2020
- Boehringer Speeding Up Growth of Jardiance on Organization, Alliance Rejig; 40 Billion Yen Japan Sales Likely in 2020
December 11, 2020
- Ono Newly Files Opdivo as First-Line Treatment for Gastric Cancer with Additional Data
December 11, 2020
- Aducanumab Submitted in Japan, but Decision Unlikely to Come Until Next Autumn
December 11, 2020
- Nichi-Iko Recalls 4 More Products Including Theophylline due to Deviations from Approved Specifications
December 11, 2020
- Kyowa Kirin to Carry Out Novel Target Discovery Using US Firm’s AI-Platform
December 11, 2020
- Kobayashi Kako Recalls Trigger Shipment Control for Kaken's Itraconazole Product
December 11, 2020
- (Update) Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 10, 2020
- Biogen Files Japan NDA for Aducanumab
December 10, 2020
- Takeda Aiming for Sales of 5 Trillion Yen by FY2030, Sees It Realistic Target with Strong Pipeline
December 10, 2020
- Pfizer Files Abrocitinib in Japan; 3rd Oral JAK Inhibitor for Atopic Dermatitis
December 10, 2020
- With Contaminated Itraconazole, Patients Might Have Taken Sleep Inducer at 10-20 Times Regular Dosage
December 9, 2020
- Criminal Charges Sought against 3 Wholesalers over Bid-Rigging, Mediceo Excluded
December 9, 2020
- Takeda’s HAE Med Takhzyro Approved in China
December 9, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…